1.The study on opioid switching for the purpose of the quality of life improvement in the gynecologic cancer
Nao Suzuki ; Ayako Yoshida ; Yuko Nakagawa ; Miho Hatano ; Noriyuki Yokomichi ; Shinji Hosonuma ; Norihito Yoshioka ; Tatsuru Ohara ; Akiko Tozawa ; Kazushige Kiguchi
Palliative Care Research 2012;7(2):363-367
Oxycodone controlled-release (CR) tablets are used as a first-line opioid analgesic for cancer pain. However, use of oxycodone CR tablets is associated with toxicities such as drowsiness and constipation, leading to deterioration of the quality of life (QOL), especially in patients with gynecologic cancer. In contrast, fentanyl has a superior toxicity profile while still showing a strong analgesic effect. Although fentanyl has been approved for switching from opioid, there have been no Japanese studies of patients with gynecologic cancer who were switched to transdermal fentanyl after experiencing toxicity during therapy with oxycodone CR. More importantly early introduction of palliative therapy for pain has not been adopted routinely in the management of gynecologic cancer. Thus, it appears that treatment for patients with gynecologic cancer remains unsatisfactory at present. We conducted research into improvement of the toxicity profile and pain control with the aim of improving QOL for patients with gynecologic cancer. We showed that pain, drowsiness, and constipation could be significantly improved in gynecologic cancer patients as a result of switching to transdermal fentanyl therapy at an early stage.
Result Analysis
Print
Save
E-mail